Streetbeat News

Stock Prices

ABBV

ALVO

TEVA

Teva Pharmaceuticals and Alvotech announced FDA approval for Simlandi, an interchangeable biosimilar to AbbVie's Humira, for various conditions. Simlandi, exclusively commercialized by Teva in the U.S., is the first high-concentration, citrate-free biosimilar to Humira with interchangeability status. This allows pharmacy-level substitution without prescriber consultation. Teva and Alvotech's strategic partnership, initiated in 2020, was recently extended. Additionally, Teva formed a partnership with Jiangsu Nhwa Pharmaceutical for the marketing of Austedo. Following the news, TEVA and ALVO stocks saw significant premarket gains.

Portfolio Pulse from Vandana Singh

February 26, 2024 | 1:49 pm

AGTI

Agiliti shares surged following the announcement that it will be taken private by THL Partners, indicating a significant corporate action that could affect its stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:49 pm

HCP

HashiCorp's stock price increased following an upgrade by Morgan Stanley from Equal-Weight to Overweight, with a raised price target from $23 to $30.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:48 pm

MU

Micron Technology, Inc. has announced the commencement of volume production of its HBM3E solution, leading to an increase in its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:47 pm

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

ALT

Kerrisdale Capital has confirmed to Benzinga that they continue to hold a short position on Altimmune (ALT), indicating a bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:45 pm

POOL

Oppenheimer analyst Scott Schneeberger maintains an Outperform rating on Pool Corporation (NASDAQ:POOL) and raises the price target from $370 to $407.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:45 pm

AAPL

NVDA

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) inaugurated its first chip plant in Japan, a move aimed at diversifying supply chains amid U.S.-China trade tensions. This expansion is part of TSMC's global strategy, including a $40 billion investment in Arizona. The company, a key supplier to Nvidia and Apple, is responding to geopolitical pressures for local operations. Additionally, Cathie Wood's Ark ETF sold TSMC and Nvidia shares, reallocating investments towards emerging software companies. TSMC's stock has gained 28% YTD, while Nvidia's stock is up 64%.

Portfolio Pulse from Anusuya Lahiri

February 26, 2024 | 1:44 pm

ITRI

Itron's stock price increased following the announcement of its Q4 financial results, which surpassed expectations. Additionally, the company provided Q1 guidance that exceeded analysts' estimates.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:37 pm

ITRI

Itron projects its full-year 2024 revenue to be between $2.275 billion and $2.375 billion, surpassing the estimated $2.292 billion. Additionally, the company anticipates its adjusted EPS to range from $3.40 to $3.80, exceeding the estimated $3.12.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm